1682P Development of an ex vivo RNA-based predictive assay for tumor tissue explants

Tumor tissue explants are an attractive tool for personalized predictive tests, however their use is compromised by subjective nature of morphological assessment drug response. We aimed to identify reporter genes, which rapidly change level expression in drug-sensitive but not drug-resistant tumors. Fresh tumor tissues were obtained from patients with non-small cell lung cancer (NSCLC) undergoing surgery. 0.4-mm-thick slices generated a chopper. NSCLC cultured 24 hours standard media containing either 8 or 16 mkg/ml gefitinib no (control). NGS-based transcriptome analysis was performed EGFR-mutated (n = 4) and non-mutated 5) tumors before after exposure. Thirty genes responsive exposure EGFR-mutant the EGFR wild-type explants. There several demonstrating evident up-regulation responders, e.g., HSPA1A (a member heat shock protein 70 family), RSPO3 component receptor tyrosine kinase signaling pathways) CDKN1C suppressor gene capable causing cycle arrest). Some downregulated response tumors, MUC13, contributes progression via activation ERK/JNK/p38 cascade. The data replicated PCR tests both samples analyzed RNAseq additional This study revealed number gefitinib-responsive may serve as RNA markers sensitivity ex vivo assay. Appropriately designed can potentially be used small samples, biopsies. It remains studied, whether suggested approach feasible prediction other targeted cytotoxic drugs.